Exploratory Study Comparing Prasugrel and Clopidogrel for Inhibition of Branch atheromatous disease (BAD) Progression

Inoue Hiroyasu0 个研究点目标入组 50 人开始时间: 2022年6月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients with lesions larger than 15 mm in diameter in the region of the lenticulostriate artery on diffusion-weighted MRI, and in the region of the pontine paramedian artery , where the infarcted lesion abuts the ventral side of the pons base, or whose infarction in the same region does not meet the above criteria but whose symptoms progress between onset and hospital visit.
•(2) Patients who are hospitalized within 48 hours of onset
•(3) Patients with hypertension, diabetes, dyslipidemia, chronic kidney disease, or history of cerebral infarction
•(4) Patients aged 20 years or older on the date of enrollment
•(5) Patients who have obtained written consent to participate in this study from the patient or the patient's surrogate.

•(1) Patients taking antiplatelet drugs other than aspirin
•(2) Patients with more than 50% stenotic lesion in the main artery branching the responsible vessel
•(3) Patients with atrial fibrillation
•(4) Patients who are bleeding or at high risk of bleeding
•(hemophilia, intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.)
•(5) Patients taking oral anticoagulants
•(6) Patients who used thrombolytic therapy (alteplase) for hyperacute stroke
•(7) Patients with severe paralysis of the upper or lower limbs at the time of admission (corresponding NIHSS score of 4 = equivalent to MMT0)
•(8) Patients with hypersensitivity to clopidogrel or prasugrel
•(9) Patients who are unable to undergo MRI imaging due to non-MRI compatible pacemakers, other metal implants, claustrophobia, etc.
•(10) Other patients deemed inappropriate as research subjects by the principal/assistant investigator

发起方

Inoue Hiroyasu